Science strides toward controlled longevity. Thousands of pet dogs now join history’s largest companion animal trials, testing drugs potentially extending lives up to 30%. Impacts span pets to human treatments.

Two Landmark Trials

US hosts parallel dog anti-aging projects: STAY (Loyal company) and TRIAD (Dog Aging Project).

STAY administers LOY-002 pill to 1,300 small dogs >10 years—mimics calorie restriction benefits. TRIAD tests rapamycin (Rapa Nui immunosuppressant) on 850 larger dogs.

Pioneering yet distinct: Loyal commercial/secretive; TRIAD academic/open, led by Matt Kaeberlein (U. Washington). Rapamycin shows early cardiovascular gains, targets aging hallmarks—inflammation, autophagy—potentially 12-24 extra human years.

Beyond Dogs: Bridge to Human Treatments

Dogs’ short lifespans ideal for anti-aging tests. Unlike mice, canines share human environments/habits/genetic diversity—results biologically closer.

Expert Manuel Collado (CNB-CSIC): dog trials uniquely mirror human aging realities.

Rapamycin promising but risky (immunosuppression). Salvador Macip (molecular medicine prof): high doses dangerous in humans.

Senior dog positives fuel safe human hopes. Trials extend dog quality-life while keying therapies past 100-year averages.

Longevity Mindset Shift

Studies signal biotech evolution: beyond curing diseases, prevent/delay aging. Dog-human translation pending, but life-extension drugs milestone.

Optimal: healthier longer pet lives; data designs future therapies. Dogs pioneer revolution redefining life/time.

STAY/TRIAD trials launch biotech era. Years from human proof, dogs lead—unlocking unimaginable lifespans.

Reference:

• Loyal/Give dogs more healthy years. Link
• Springer Nature Link/Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project. Link

Esta entrada también está disponible en: Español